Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics

Najoua Lalaoui; Kay Haenggi; Gabriela Brumatti; Diep Chau; Nhu-Y N Nguyen; Lazaros Vasilikos; Lisanne M Spilgies; Denise A Heckmann; Chunyan Ma; Margherita Ghisi; Jessica M Salmon; Geoffrey M Matthews; Elisha de Valle; Donia M Moujalled; Manoj B Menon; Sukhdeep Kaur Spall; Stefan P Glaser; Jennifer Richmond; Richard B Lock; Stephen M Condon; Raffi Gugasyan; Matthias Gaestel; Mark Guthridge; Ricky W Johnstone; Lenka Munoz; Andrew Wei; Paul G Ekert; David L Vaux; W Wei-Lynn Wong; John Silke

Journal article

Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics

Najoua Lalaoui, Kay Haenggi, Gabriela Brumatti, Diep Chau, Nhu-Y N Nguyen, Lazaros Vasilikos, Lisanne M Spilgies, Denise A Heckmann, Chunyan Ma, Margherita Ghisi, Jessica M Salmon, Geoffrey M Matthews, Elisha de Valle, Donia M Moujalled, Manoj B Menon, Sukhdeep Kaur Spall, Stefan P Glaser, Jennifer Richmond, Richard B Lock, Stephen M Condon Show all

Cancer Cell | CELL PRESS | Published : 2016

DOI: 10.1016/j.ccell.2016.01.006

University of Melbourne Researchers

David Vaux Author Medical Biology (W.E.H.I.)

Gabriela Brumatti Author Medical Biology (W.E.H.I.)

Najoua Lalaoui Author Medical Biology (W.E.H.I.)

John Silke Author Medical Biology (W.E.H.I.)

Paul Ekert Author Paediatrics Royal Children's Hospital

Related Projects (1)

Molecular Dissection Of Aberrant Il6/Gp130 And Tgfb Signaling In The Pathogenesis Of Interstitial Pneumonitis

Interstitial pneumonia (IP) is frequently observed in the group of lung diseases which affect the transfer of oxygen from inhaled air into t..

Grants

Awarded by NHMRC

Awarded by NHMRC IRIISS grant

Awarded by Deutsche Forschungsgemeinschaft

Awarded by SNSF project

Funding Acknowledgements

We thank V. Dixit for Ripk3-/-, H. Korner for Tnfr1-/-, W. Alexander for Mlkl-/-, S. Hedrick for Casp8fl/fl, M. Pasparakis for Mapk14fl/fl mice, and the Burnet Institute Immuno Monitoring Facility for technical assistance. This work was supported by NHMRC grants (1016647, 461221, 1016701, 1025594, 1046984, 1046010, 1025239, 637367, 1008131, 1081221, 1051235 and 1057905), Cancer Council Victoria grant-in-aid to S.P.G., NHMRC fellowships to J.S. (541901, 1058190) and D.V. (1020136), Association pour la Recherche sur le Cancer (ARC) fellowship to N.L., Peter Muller fellowship to K.H. with additional support from the Australian Cancer Research Fund, Victorian State Government Operational Infrastructure Support, NHMRC IRIISS grant (361646), grant SFB566 from Deutsche Forschungsgemeinschaft (M. Gaestel), and SNSF project grant (310030-138085). S.C. is an employee, and J.S. and D.V. are on the SAB of TetraLogic Pharmaceuticals. A.W. is performing a clinical trial for Tetralogic with birinapant. J.S, D.V., and N.L. are inventors of a patent describing the combination of smac-mimetic plus p38 inhibitor to treat cancer.